lexatumumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458270193

| image =

| type = mab

| mab_type = mab

| source = u

| target = TRAIL-R2

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 845816-02-6

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 967Q0SJD77

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06611

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=6346 | H=9832 | N=1720 | O=2002 | S=42

}}

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.{{cite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/lexatumumab.pdf | title = Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab | publisher = American Medical Association | archive-url = https://web.archive.org/web/20120220193123/http://www.ama-assn.org/ama1/pub/upload/mm/365/lexatumumab.pdf | archive-date=2012-02-20 }}{{cite journal | vauthors = Marini P | title = Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2 | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 6 | pages = 539–46 | date = December 2006 | pmid = 17243490 | doi = | url = }}

HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.{{cite web |url=http://www.hgsi.com/trail-receptor-antibodies-5.html |title=TRAIL Receptor Antibodies | work = Human Genome Sciences, Inc. |access-date=2010-05-12 |url-status=dead |archive-url=https://archive.today/20080516025527/http://www.hgsi.com/trail-receptor-antibodies-5.html |archive-date=2008-05-16 }}

Development was discontinued in 2015.{{cite web|title=Lexatumumab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800017268| publisher = Springer Nature Switzerland AG |language=en}}